IO Biotech Announces Abstract Accepted for Mini Oral Presentation at IASLC 2023 World Conference on Lung Cancer
July 25 2023 - 4:05PM
IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical
company developing novel, immune-modulating cancer therapies based
on its T-win® technology platform, announced today an abstract
related to the company’s Phase 2 basket trial (IOB-022/KN-D38) with
IO102-IO103 as an investigational agent in combination with
KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in solid
tumors has been accepted for a Mini Oral presentation at the IASLC
2023 World Conference on Lung Cancer (WCLC). The conference is
being hosted by the International Association for the Study of Lung
Cancer (IASLC) in Singapore from September 9-12, 2023.
“We are pleased that the WCLC has accepted the
abstract on our Phase 2 trial showing the preliminary results of
using IO102-IO103 in combination with pembrolizumab as a first line
treatment for lung adenocarcinoma,” said Mai-Britt Zocca, PhD,
President and CEO of IO Biotech. “Based on the encouraging interim
data we have seen, we are continuing to enroll patients with
non-small cell lung cancer in this trial.”
Abstract Details
Abstract Title: Ph 2 Trial of IO102-IO103
Vaccine Plus Pembrolizumab: Preliminary Results for the First-line
Treatment of Lung AdenocarcinomaSession: MA15 - Bringing New
Discoveries into Early Phase Clinical TrialsSession Date &
Time: September 12, 2023 at 10:45 AM - 11:45 AMPresenter: Jonathan
Riess, M.D.
About IO102-IO103
IO102-IO103 is an investigational
immune-modulating cancer vaccine designed to target the
immunosuppressive mechanisms mediated by the proteins indoleamine
2,3-dioxygenase (IDO) and PD-L1. The company is currently
conducting a Phase 3 trial (IOB-013/KN-D18; Clinical Trials.gov:
NCT05155254) evaluating IO102-IO103 in combination with
pembrolizumab in first-line advanced melanoma patients, and a Phase
2 basket trial (IOB-022/KN-D38; NCT05077709).
About IOB-022/KN-D38 Phase 2 Solid Tumor Basket
Trial
IOB-022/KN-D38, (Clinical Trials.gov:
NCT05077709) is a non-comparative, open label trial to investigate
the safety and efficacy of IO102-IO103 in combination with
pembrolizumab in each of the following first-line advanced cancers:
non-small cell lung cancer (NSCLC), squamous cell carcinoma of the
head and neck (SCCHN), and urothelial bladder cancer (UBC). The
clinical trial is sponsored by IO Biotech and conducted in
collaboration with Merck. IO Biotech maintains global commercial
rights to IO102-IO103.
About IO Biotech
IO Biotech is a clinical-stage biopharmaceutical
company developing novel, immune-modulating cancer vaccines based
on its T-win® vaccine platform. The T-win platform is a novel
approach to cancer vaccines designed to activate T cells to target
the most important immunosuppressive cells in the tumor
microenvironment. IO Biotech is advancing in clinical trials its
lead cancer vaccine candidate, IO102-IO103, targeting IDO and
PD-L1, and through preclinical development its other pipeline
candidates. IO Biotech is headquartered in Copenhagen, Denmark and
has US headquarters in New York, New York.
For further information, please visit
www.iobiotech.com.
Forward-Looking Statement
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. Forward-looking statements, including
regarding future clinical trials and results, are based on IO
Biotech’s current assumptions and expectations of future events and
trends, which affect or may affect its business, strategy,
operations or financial performance, and actual results and other
events may differ materially from those expressed or implied in
such statements due to numerous risks and uncertainties.
Forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted or quantified.
Because forward-looking statements are inherently subject to risks
and uncertainties, you should not rely on these forward-looking
statements as predictions of future events. These forward-looking
statements speak only as of the date hereof and should not be
unduly relied upon. Except to the extent required by law, IO
Biotech undertakes no obligation to update these statements,
whether as a result of any new information, future developments or
otherwise.
Contact:Maryann Cimino, Director of Investor
Relations IO Biotech, Inc.617-710-7305mci@iobiotech.com
IO Biotech (NASDAQ:IOBT)
Historical Stock Chart
From Apr 2024 to May 2024
IO Biotech (NASDAQ:IOBT)
Historical Stock Chart
From May 2023 to May 2024